Freestone Grove Partners LP Buys Shares of 30,673 National Health Investors, Inc. $NHI

Freestone Grove Partners LP acquired a new stake in National Health Investors, Inc. (NYSE:NHI) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 30,673 shares of the real estate investment trust’s stock, valued at approximately $2,339,000.

Other large investors also recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new position in National Health Investors during the 2nd quarter worth about $1,443,000. Hsbc Holdings PLC purchased a new position in National Health Investors in the second quarter worth approximately $7,121,000. Canada Pension Plan Investment Board acquired a new position in shares of National Health Investors during the second quarter worth $1,228,000. Legal & General Group Plc purchased a new position in shares of National Health Investors in the 2nd quarter valued at about $21,745,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in National Health Investors during the second quarter worth approximately $1,870,000. 62.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NHI has been the topic of several research analyst reports. BMO Capital Markets cut their price target on National Health Investors from $90.00 to $80.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. Weiss Ratings lowered National Health Investors from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, June 12th. Truist Financial lowered their price target on shares of National Health Investors from $89.00 to $81.00 and set a “buy” rating on the stock in a research note on Friday, June 12th. Wells Fargo & Company lowered their price target on National Health Investors from $84.00 to $79.00 and set an “equal weight” rating on the stock in a report on Monday, June 1st. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on shares of National Health Investors from $85.00 to $80.00 and set a “hold” rating for the company in a report on Thursday, June 25th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $83.86.

National Health Investors Stock Performance

NYSE NHI opened at $71.96 on Friday. The business’s 50-day moving average price is $75.68 and its 200 day moving average price is $78.76. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.81. National Health Investors, Inc. has a twelve month low of $67.94 and a twelve month high of $91.38. The company has a market capitalization of $3.53 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 3.86 and a beta of 0.51.

National Health Investors (NYSE:NHI) last released its earnings results on Monday, August 10th. The real estate investment trust reported $1.19 earnings per share (EPS) for the quarter. National Health Investors had a net margin of 38.56% and a return on equity of 10.89%. The firm had revenue of $121.32 million during the quarter. During the same quarter in the previous year, the firm posted $1.22 earnings per share. National Health Investors’s revenue for the quarter was up 1.6% compared to the same quarter last year. National Health Investors has set its FY 2026 guidance at 4.740-4.790 EPS. On average, research analysts predict that National Health Investors, Inc. will post 4.78 earnings per share for the current year.

National Health Investors Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.92 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.68 annualized dividend and a dividend yield of 5.1%. National Health Investors’s payout ratio is currently 106.36%.

Insiders Place Their Bets

In other news, Director Robert A. Mccabe, Jr. purchased 890 shares of the stock in a transaction on Monday, June 15th. The stock was purchased at an average price of $71.65 per share, with a total value of $63,768.50. Following the completion of the transaction, the director owned 44,159 shares in the company, valued at approximately $3,163,992.35. The trade was a 2.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO D. Eric Mendelsohn acquired 1,500 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $68.84 per share, for a total transaction of $103,260.00. Following the completion of the acquisition, the chief executive officer owned 133,316 shares in the company, valued at approximately $9,177,473.44. This trade represents a 1.14% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 2.70% of the company’s stock.

About National Health Investors

National Health Investors, Inc (NYSE: NHI) is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company’s portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.